ClinicalTrials.gg
RecruitingNCT06830343Updated Apr 6, 2026

The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity

A Phase 1 interventional study of SYH9017 and Placebo in Overweight or Obesity, sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

How we know · 8 judgments

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 601 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Planned enrollment
344th of 503
66 · median 120
Started
2025
with 113 others
Phase 1
93 of 601
29 open now
Primary completion
2026-08
later than 77 of 280 live
Registered
327th of 601
by date

Among the 601 studies in Obesity with a site in China, this one is the 344th largest by planned enrollment of the 503 interventional ones that give a count, is one of 114 that started in 2025, is one of 93 in phase 1, reaches primary completion later than 77 of the 280 other live ones, and was the 327th registered.

Obesity

11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 601 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 601 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, single-center, dose-escalation, single ascending dose and multiple ascending dose study of SYH9017 in Chinese participants with overweight and obesity.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

Keywords

  • overweight or obesity
04

In context

Obesity Reclassified

11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's planned enrollment of 66 is close to the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. is the lead sponsor of 26 studies on the registry; 4 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chinese male or female adult participants aged 18-60 years (inclusive) with overweight or obesity, with no less than one-third of the participants of either gender;
  2. SAD phase: (BMI) = weight (kg)/height\^2 , with BMI in the range of 24.0-28.0 kg/m\^2 (inclusive); MAD phase: Weight ≥70 kg (for males) or ≥60 kg (for females), and BMI = weight (kg)/height\^2 , with BMI ≥28.0 kg/m\^2;
  3. Weight change \<5% in the 3 months prior to screening (can be based on self-report); calculated as: (weight 12 weeks before screening - weight at screening) / weight at screening * 100%;
  4. Vital signs, physical examination, 12-lead , chest X-ray (anteroposterior view), abdominal color Doppler ultrasound, clinical laboratory tests (complete blood count, urinalysis, blood biochemistry, , coagulation function, infectious disease screening, thyroid function, calcitonin, etc.) show normal results or abnormal results deemed not by the investigator;
  5. Able to read and understand the written related to the study information, fully aware of the study content, process, and possible adverse reactions, voluntarily sign the informed consent form before the trial, and ensure that they will personally participate in any procedures; Participants and their partners agree to use effective non-hormonal methods (such as condoms, inert intrauterine devices, female barrier methods [cervical cap or diaphragm with spermicide], vaginal contraceptive rings, etc.) from the time of signing the informed consent form until 6 months after the last dose, or have already adopted permanent contraception measures (such as bilateral tubal ligation, vasectomy, etc.); Male participants do not plan to donate sperm from the time of signing the informed consent form until 6 months after the last dose, and female participants do not plan to donate eggs from the time of signing the informed consent form until 6 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. A history of severe drug or food allergies, or any participant who is judged by the investigator to potentially be allergic to the drug;
  2. A history of significant diseases involving the pancreas, liver, kidneys, gastrointestinal tract, skin, cardiovascular system, respiratory system, hematological system, central nervous system, or other conditions that may endanger the safety of participants or affect the absorption, metabolism, or excretion of the study drug, and are deemed unsuitable for inclusion by the investigator;
  3. A history of (except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix), psychiatric disorders (such as depression, schizophrenia, bipolar disorder, or a history of suicidal ideation or behavior), epilepsy, acute biliary disease, or confirmed acute or chronic pancreatitis; participants judged by the investigator to be unsuitable for participation in this clinical study;
  4. Diagnosed with diabetes, thyroid dysfunction (abnormal TSH, FT3, or FT4 levels), Cushing's syndrome, polycystic ovary syndrome, a history of glucagonoma or pheochromocytoma, or other endocrine diseases that may affect glucose metabolism, or has experienced ≥2 episodes of severe hypoglycemia or recurrent symptomatic hypoglycemia;
  5. A personal or family history of medullary thyroid carcinoma (MTC) or a history of multiple endocrine neoplasia type 2 (MEN2).
  6. Any one of the following criteria is met:

    i. Participants with one or more abnormal vital signs: body temperature \<35.5°C or >37.2°C, pulse rate \<50 beats per minute or >100 beats per minute, systolic blood pressure ≥160 mmHg or \<90 mmHg, diastolic blood pressure ≥100 mmHg or \<60 mmHg. A single retest is allowed, and participants with abnormalities in both tests will be excluded; ii. Any of the following laboratory abnormalities: a) Fasting plasma glucose ≥7.0 mmol/L or fasting plasma glucose \<3.9 mmol/L or level >6.5%; b) or ALT >2 times the (ULN), total >1.5 times ULN, deemed by the investigator; c) Estimated (eGFR) \<90 mL/min/1.73m²; d) Serum amylase or lipase >3 times ULN; e) Blood low-density lipoprotein cholesterol (LDL-C) ≥4.40 mmol/L; f) Triglycerides (TG) ≥5.65 mmol/L.

  7. During the multiple-dose phase: Use of any approved or unapproved drugs or products that may affect body weight within 6 months prior to screening, including but not limited to orlistat, phentermine-topiramate, naltrexone-bupropion, systemic medications (administered intravenously, orally, or intra-articularly), antidepressants (selective serotonin reuptake inhibitors (SSRIs), noradrenaline reuptake inhibitors (SNRIs), tricyclics, tetracyclics, etc.), psychotropic medications or sedative drugs (such as imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproate, valproate derivatives, lithium salts), etc.; or use of traditional Chinese medicines, health supplements, meal replacements, or antibiotic drugs or probiotic preparations that influence gut microbiota and thereby affect body weight; or having undergone bariatric surgery within 6 months prior to screening;
  8. Use of glucagon-like peptide-1 (GLP-1) receptor agonists, GLP-1 analogs (such as liraglutide, dulaglutide, lixisenatide, exenatide, albiglutide, benraliptide, polyethylene glycol loxenatide, etc.) or any dipeptidyl peptidase-4 (DPP-4) inhibitors or glucose-dependent insulinotropic polypeptide (GIP) receptor agonists within 6 months prior to signing the form.
  9. Use of any prescription medications, over-the-counter medications, traditional Chinese patent medicines, herbal remedies, vitamin dietary supplements, or health products within 4 weeks prior to signing the informed consent form;
  10. Habitual intake of or consumption of excessive amounts of xanthine or caffeine-containing foods, beverages, or other substances that may affect drug absorption, distribution, metabolism, or excretion within 1 month prior to screening or within 72 hours before using the investigational drug. Examples include: coffee (more than 1100 mL per day), tea (more than 2200 mL per day), cola (more than 2200 mL per day), energy drinks (more than 1100 mL per day), chocolate (more than 510 g per day);
  11. Undergone surgery (including cosmetic, dental, and oral surgeries) within 6 months prior to screening or planned during the trial period, or plans to engage in vigorous physical activity (including contact sports or collision sports) during the trial period;
  12. A history of drug abuse or a positive drug screening test within 1 year prior to signing the informed consent form;
  13. Loss of blood or donation of more than 400 mL of blood within 3 months prior to signing the informed consent form, or receipt of blood transfusions or use of blood products;
  14. Consumption of more than 14 units of alcohol per week (1 unit = 285 mL of beer; 25 mL of spirits; 150 mL of wine) within 3 months prior to signing the informed consent form, or consumption of any alcohol-containing products within 48 hours before using the investigational drug; positive baseline alcohol test (>0 mg/100 mL) or inability to abstain from alcohol during the trial period;
  15. Smoking ≥5 cigarettes daily within 6 months prior to signing the informed consent form, smoking within 48 hours before using the investigational drug, or inability to cease the use of any tobacco products during the trial period;
  16. Participation in any clinical trial involving investigational drugs or medical devices within 3 months prior to signing the informed consent form;
  17. Pregnant and/or breastfeeding women, or women of with a positive pregnancy test at screening and before dosing;
  18. A history of vasovagal syncope or hemophobia, or difficulty with venipuncture for any reason, making it intolerable;
  19. Difficulty with subcutaneous injection administration;
  20. Any other factors deemed by the investigator to make the participant unsuitable for participation in the trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    SYH9017 SAD experimental group

    Subjects in SAD experimental groups will receive a single subcutaneous injection of SYH9017 on Day 1

    Drug: SYH9017

  • Placebo comparator
    Placebo SAD group

    Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 1

    Drug: Placebo

  • Experimental
    SYH9017 MAD experimental group

    Subjects in MAD experimental groups will receive subcutaneous injection of SYH9017 every 4weeks

    Drug: SYH9017

  • Placebo comparator
    Placebo MAD group

    Subjects in MAD placebo groups will receive subcutaneous injection of placebo every 4weeks

    Drug: Placebo

  • Active comparator
    Positive Control MAD group

    Subjects in MAD active comparator groups will receive subcutaneous injection of placebo every weeks

    Drug: Wegovy ®

Interventions

  • DrugSYH9017

    subcutaneous injection once time in SAD and four times in MAD

  • DrugPlacebo

    subcutaneous injection once time in SAD and four times in MAD

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    subcutaneous injection once a week

07

What researchers measure

Primary outcomes

  1. Incidence of AEs following single-dose administration of SYH9017 Description:

    Time frame: up to 49 days after the dosing

  2. Incidence of AEs following multiple doses administration of SYH9017AEs of SYH 9017 following multiple doses

    Time frame: up to 140 days after the last dosing

Secondary outcomes

  1. The Cmax of SYH9017 following single-dose

    Time frame: up to 49 days after the dosing

  2. The AUC of SYH9017 following single-dose

    Time frame: up to 49 days after the dosing

  3. The Tmax of SYH9017 following single-dose

    Time frame: up to 49 days after the dosing

  4. The t1/2 of SYH9017 following single-dose

    Time frame: up to 49 days after the dosing

  5. The CL/F of SYH9017 following single-dose

    Time frame: *Time Frame:up to 49 days after the dosing

  6. The Vz/F of SYH9017 following single-dose

    Time frame: up to 49 days after the dosing

  7. The proportion of patients (%) who developed binding antibodies and neutralizing antibodies following single-dose administration of SYH9017

    Time frame: up to 49 days after the dosing

  8. The percentage change in body weight from baseline of SYH9017 following single-dose

    Time frame: up to 49 days after the dosing

  9. The percentage change in waist circumference from baseline of SYH9017 following single-dose

    Time frame: up to 49 days after the dosing

  10. The Cmax of SYH9017 following multiple doses

    Time frame: up to 140 days after the last dosing

  11. The AUC of SYH9017 following multiple doses

    Time frame: up to 140 days after the last dosing

  12. The Tmax of SYH9017 following multiple doses

    Time frame: up to 140 days after the last dosing

  13. The t1/2 of SYH9017 following multiple doses

    Time frame: up to 140 days after the last dosing

  14. The CL/F of SYH9017 following multiple doses

    Time frame: up to 140 days after the last dosing

  15. The Vz/F of SYH9017 following multiple doses

    Time frame: up to 140 days after the last dosing

  16. The Cmin of SYH9017 following multiple doses

    Time frame: up to 140 days after the last dosing

  17. The RAUC of SYH9017 following multiple doses

    Time frame: up to 140 days after the last dosing

  18. The RCmax of SYH9017 following multiple doses

    Time frame: up to 140 days after the last dosing

  19. The proportion of patients (%) who developed binding antibodies and neutralizing antibodies following multiple doses administration of SYH9017

    Time frame: up to 140 days after the last dosing

  20. The percentage change in body weight from baseline of SYH9017 following multiple doses

    Time frame: up to 140 days after the last dosing

  21. The percentage change in waist circumference from baseline of SYH9017 following multiple doses

    Time frame: up to 140 days after the last dosing

  22. The proportion of participants with ≥5% weight loss during the trial period of SYH9017 following multiple doses

    Time frame: up to 140 days after the last dosing

  23. The proportion of participants with ≥10% weight loss during the trial period of SYH9017 following multiple doses

    Time frame: up to 140 days after the last dosing

  24. The changes in body composition (including visceral, peripheral fat, and skeletal muscle) as measured by body fat analyzer after 16 weeks of treatment, compared to baseline of SYH9017 following multiple doses

    Time frame: up to 140 days after the last dosing

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Aug 2026, 17 months after the start.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 17 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2025
First posted
Feb 17, 2025
StartActual
Feb 27, 2025
Primary completionEst.
Aug 1, 2026
CompletionEst.
Oct 1, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06830343
Responsible party
Sponsor
First posted
Feb 17, 2025
Start date
Feb 27, 2025
Primary completion
Aug 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Apr 6, 2026

Study contacts

Clinical Trials Information Group officer, /
Contact
ctr-contact@cspc.cn
86-0311-69085587
Dongyang Liu, PhD
Contact
liudongyang@vip.sina.com
+86-010-82266456

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion